首页|Stereotactic body radiotherapy in pancreatic adenocarcinoma
Stereotactic body radiotherapy in pancreatic adenocarcinoma
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
国家科技期刊平台
NETL
NSTL
万方数据
维普
Background:Stereotactic body radiotherapy(SBRT)in pancreatic cancer allows high delivery of radiation doses on tumors without affecting surrounding tissue.This review aimed at the SBRT application in the treatment of pancreatic cancer.Data sources:We retrieved articles published in MEDLINE/PubMed from January 2017 to December 2022.Keywords used in the search included:"pancreatic adenocarcinoma"OR"pancreatic cancer"AND"stereo-tactic ablative radiotherapy(SABR)"OR"stereotactic body radiotherapy(SBRT)"OR"chemoradiotherapy(CRT)".English language articles with information on technical characteristics,doses and fractionation,indications,recurrence patterns,local control and toxicities of SBRT in pancreatic tumors were included.All articles were assessed for validity and relevant content.Results:Optimal doses and fractionation have not yet been defined.However,SBRT could be the standard treatment in patients with pancreatic adenocarcinoma in addition to CRT.Furthermore,the combination of SBRT with chemotherapy may have additive or synergic effect on pancreatic adenocarcinoma.Conclusions:SBRT is an effective modality for patients with pancreatic cancer,supported by clinical prac-tice guidelines as it has demonstrated good tolerance and good disease control.SBRT opens a possibility of improving outcomes for these patients,both in neoadjuvant treatment and with radical intent.
ChemoradiotherapyPancreatic adenocarcinomaRadiotherapyStereotactic body radiotherapyStereotactic ablative radiotherapy
Carolina de la Pinta
展开 >
Radiation Oncology Department,Ramón y Cajal University Hospital,IRYCIS,Alcalá University,28034 Madrid,Spain
国家科技期刊平台
